Earnings History Data for Revance Therapeutics (RVNC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Revance Therapeutics

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	AH		RVNC	Revance Therapeutics	612.00	-0.37	-0.35	0.00	Revance Therapeutics GAAP EPS of -$0.37 beats by $0.01, revenue of $59.88M misses by $8.3M [11/7/2024 6:10 PM]	3.74	-2.04 (-35.29%)	4.30	-1.48 (-25.61%)	2.30 - 9.74	11,639,417	2,190,000	1,175,435
Revance Therapeutics GAAP EPS of -$0.37 beats by $0.01, revenue of $59.88M misses by $8.3M [11/7/2024 6:10 PM] Revance Therapeutics sinks amid `going concern' disclosure [11/7/2024 8:45 PM] Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update [2024-11-07 04:05PM]
08-08-2024	AH		RVNC	Revance Therapeutics, Inc.	321.70	-0.36	-0.48	-0.80	Revance Therapeutics GAAP EPS of -$0.36 beats by $0.12, revenue of $65.3M misses by $0.99M [8/8/2024 4:29 PM]	3.48	0.53 (18.14%)	3.12	0.17 (5.76%)	2.30 - 22.45	4,600,788	1,850,000	7,409
Revance Therapeutics GAAP EPS of -$0.36 beats by $0.12, revenue of $65.3M misses by $0.99M [8/8/2024 4:29 PM]
09-05-2024	AH		RVNC	Revance Therapeutics, Inc.	386.38	-0.54	-0.66	-0.74	Revance Therapeutics GAAP EPS of -$0.58, revenue of $51.94M [5/9/2024 4:50 PM]	3.37	-0.92 (-21.56%)	4.03	-0.26 (-6.06%)	3.00 - 36.70	7,793,961	1,730,000	14,498
Revance Therapeutics GAAP EPS of -$0.58, revenue of $51.94M [5/9/2024 4:50 PM]
28-02-2024	AH		RVNC	Revance Therapeutics	482.00	-0.62	-0.79	0.00	Revance Therapeutics GAAP EPS of -$0.62 beats by $0.19, revenue of $69.8M beats by $7.7M [2/28/2024 4:17 PM]	7.16	1.50 (26.50%)	6.12	0.46 (8.13%)	5.00 - 37.98	6,290,656	1,270,000	132,956
Revance Therapeutics GAAP EPS of -$0.62 beats by $0.19, revenue of $69.8M beats by $7.7M [2/28/2024 4:17 PM]
08-11-2023	AH		RVNC	Revance Therapeutics, Inc.	798.63	-0.74	-1.10	-1.17	Revance Therapeutics GAAP EPS of -$1.63 misses by $0.69, revenue of $56.8M misses by $1.94M [11/8/2023 4:23 PM]	6.89	-1.44 (-17.29%)	7.25	-1.08 (-12.97%)	6.83 - 37.98	3,373,850	1,790,000	12,281
Revance Therapeutics GAAP EPS of -$1.63 misses by $0.69, revenue of $56.8M misses by $1.94M [11/8/2023 4:23 PM]
08-08-2023	AH		RVNC	Revance Therapeutics, Inc.	1,910	-0.80	-0.72	-0.88	Revance Therapeutics GAAP EPS of -$0.80 misses by $0.01, revenue of $58.13M misses by $0.81M [8/8/2023 4:40 PM]	20.11	-1.88 (-8.57%)	22.30	0.31 (1.41%)	16.47 - 37.98	4,270,886	1,450,000	13,953
Revance Therapeutics GAAP EPS of -$0.80 misses by $0.01, revenue of $58.13M misses by $0.81M [8/8/2023 4:40 PM]
09-05-2023	AH	4:05 PM ET (May 9)	RVNC	Revance Therapeutics, Inc.	2,900	-0.74	-0.75	-0.94	Revance Therapeutics GAAP EPS of -$0.74, revenue of $49.3M [5/9/2023 4:48 PM]	36.23	-1.38 (-3.66%)	34.00	-3.61 (-9.60%)	11.27 - 37.98	3,844,267	1,360,000	23,205
Revance Therapeutics GAAP EPS of -$0.74, revenue of $49.3M [5/9/2023 4:48 PM]
28-02-2023	AH	4:05 PM ET (Feb 28)	RVNC	Revance Therapeutics, Inc.	2,720	-1.82	-1.04	-0.93	Revance Therapeutics GAAP EPS of -$1.82 misses by $0.78, revenue of $49.9M beats by $4.8M [2/28/2023 4:40 PM]	32.32	-2.38 (-6.86%)	34.70	0.0 (0.00%)	11.27 - 36.61	2,132,019	1,390,000	2,249
Revance Therapeutics GAAP EPS of -$1.82 misses by $0.78, revenue of $49.9M beats by $4.8M [2/28/2023 4:40 PM]
08-11-2022	AH	4:05 PM ET (Nov 8)	RVNC	Revance Therapeutics, Inc.	1,770	-1.17	-0.85	-1.10	Revance Therapeutics GAAP EPS of -$1.17 misses by $0.23, revenue of $29M beats by $0.76M [11/8/2022 4:34 PM]	20.30	-1.09 (-5.07%)	20.90	-0.49 (-2.29%)	11.27 - 30.95	2,373,683	1,300,000	149,546
Revance Therapeutics GAAP EPS of -$1.17 misses by $0.23, revenue of $29M beats by $0.76M [11/8/2022 4:34 PM] Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update [Nov-08-22 04:05PM]
09-08-2022	AH	4:05 PM ET (Aug 9)	RVNC	Revance Therapeutics, Inc.	1,140	-0.88	-0.91	-1.07	Revance Therapeutics GAAP EPS of -$0.88 beats by $0.03, revenue of $28.37M beats by $0.6M [8/9/2022 4:21 PM]	21.49	4.02 (23.01%)	18.34	0.87 (4.98%)	11.27 - 30.00	1,453,026	720,000	28,491
Revance Therapeutics GAAP EPS of -$0.88 beats by $0.03, revenue of $28.37M beats by $0.6M [8/9/2022 4:21 PM]
10-05-2022	AH	4:05 PM ET (May 10)	RVNC	Revance Therapeutics, Inc.	1,160	-0.94	-0.91	-1.08	Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M [5/10/2022 4:15 PM]	13.15	-1.70 (-11.47%)	14.75	-0.11 (-0.74%)	11.65 - 33.83	1,598,722	660,000	200
Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M [5/10/2022 4:15 PM] Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update [May-10-22 04:05PM] Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates [May-10-22 05:45PM]
28-02-2022	AH	4:05 PM ET (Feb 28)	RVNC	Revance Therapeutics, Inc.	928.31	-0.93	-0.98	-1.24	Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09, revenue of $25.95M beats by $1.22M [2/28/2022 4:30 PM]	15.20	1.63 (12.01%)	13.04	-0.53 (-3.91%)	11.65 - 33.83	1,309,267	590,000	2,210
Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09, revenue of $25.95M beats by $1.22M [2/28/2022 4:30 PM] Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update [Feb-28-22 04:05PM]
09-11-2021	AH	4:05 PM ET (Nov 9)	RVNC	Revance Therapeutics, Inc.	995.56	-1.10	-1.08	-1.34	Revance Therapeutics EPS beats by $0.05, misses on revenue [11/9/2021 4:11 PM]	14.63	0.71 (5.10%)	14.05	0.13 (0.93%)	13.01 - 33.83	1,654,675	960,000	1,344
Revance Therapeutics EPS beats by $0.05, misses on revenue [11/9/2021 4:11 PM] Revance Therapeutics Investor Alert [Nov-08-21 05:56PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firms Attorneys Now, Firm Investigating Possible Securities Law Violations [Nov-08-21 04:58PM] RVNC ALERT - Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) for Potential Securities Violations [Nov-08-21 04:00PM] ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm [Nov-08-21 10:00AM] Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings? [Nov-08-21 08:36AM] INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm [Nov-09-21 10:10AM] RVNC INVESTIGATION: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firms Attorneys Now, Firm Investigating Possible Securities Law Violations [Nov-09-21 02:45PM] Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update [Nov-09-21 04:05PM] Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates [Nov-09-21 05:15PM] Revance Therapeutics Shareholder Alert [Nov-09-21 06:45PM] Revance Therapeutics Inc (RVNC) Q3 2021 Earnings Call Transcript [Nov-10-21 04:02AM] INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm [Nov-10-21 09:45AM] Revance Therapeutics Shareholder Notice [Nov-10-21 06:47PM] Revance to Participate in the Stifel 2021 Virtual Healthcare Conference [Nov-10-21 04:05PM]
05-08-2021	AH	4:05 PM ET (Aug 5)	RVNC	Revance Therapeutics, Inc.	2,080	-1.07	-1.14	-1.12	Revance Therapeutics EPS beats by $0.06, beats on revenue [8/5/2021 5:12 PM]	29.04	-0.79 (-2.65%)	29.83	0.0 (0.00%)	22.89 - 34.62	638,875	380,000	158,278
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update [Aug-05-21 04:05PM] Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 07:05PM]
10-05-2021	AH	4:05 PM ET (May 10)	RVNC	Revance Therapeutics, Inc.	2,060	-1.08	-1.19	-1.15	Revance Therapeutics EPS beats by $0.11, beats on revenue [5/10/2021 4:10 PM]	27.29	-0.14 (-0.51%)	27.43	0.0 (0.00%)	18.39 - 34.62	563,724	350,000	9,421
Revance Therapeutics EPS beats by $0.11, beats on revenue [5/10/2021 4:10 PM] Revance Therapeutics, Inc. to Host Earnings Call [May-10-21 02:30PM] Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update [May-10-21 04:05PM] Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 06:05PM] Is Revance Therapeutics (NASDAQ:RVNC) Weighed On By Its Debt Load? [May-11-21 08:17AM]
22-02-2021	AH	4:05 PM ET (Feb 22)	RVNC	Revance Therapeutics, Inc.	1,930	-1.24	-1.16	-0.99	Revance Therapeutics EPS beats by $0.11, beats on revenue [2/22/2021 4:12 PM]	25.85	-1.11 (-4.12%)	26.96	0.0 (0.00%)	11.78 - 34.62	763,060	399,805	30,124
Revance posts top-line results from mid-stage DaxibotulinumtoxinA upper limb spasticity study [2/22/2021 4:15 PM] Revance Therapeutics EPS beats by $0.11, beats on revenue [2/22/2021 4:12 PM] Revance Therapeutics' DaxibotulinumtoxinA For Injection Improves Muscle Tone In Mid-Stage Upper Limb Spasticity [Feb-23-21 05:58AM] Revance Reports Fourth Quarter and Full Year 2020 Financial Results [Feb-22-21 04:05PM] Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity [Feb-22-21 04:05PM] Revance Therapeutics, Inc. to Host Earnings Call [Feb-22-21 02:30PM] Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey OConnor Kolaja, to its Board of Directors [Feb-22-21 08:00AM]
09-11-2020	AH	4:05 PM ET (Nov 9)	RVNC	Revance Therapeutics, Inc.	1,760	-1.34	-1.09	-0.96	Revance Therapeutics EPS misses by $0.30, beats on revenue; updates FY20 outlook [11/9/2020 4:12 PM]	25.66	-1.94 (-7.05%)	24.10	-3.50 (-12.68%)	11.78 - 34.62	1,234,031	429,942	1,129

06-08-2020	AH	4:05 PM ET (Aug 6)	RVNC	Revance Therapeutics, Inc.	1,610	-1.12	-0.96	-0.86	Revance Therapeutics EPS misses by $0.12, misses on revenue [8/6/2020 4:31 PM]	26.56	2.98 (12.64%)	23.58	0.0 (0.00%)	9.88 - 27.97	615,699	326,960	9,951